Literature DB >> 22453240

The mechanisms of IDH mutations in tumorigenesis.

Dan Ye1, Yue Xiong, Kun-Liang Guan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22453240      PMCID： PMC3391014          DOI： 10.1038/cr.2012.51

Source DB:  PubMed          Journal:  Cell Res        ISSN： 1001-0602            Impact factor:   46.297


× No keyword cloud information.
  12 in total

Review 1.  Alterations of metabolic genes and metabolites in cancer.

Authors:  Eric K Oermann; Jing Wu; Kun-Liang Guan; Yue Xiong
Journal:  Semin Cell Dev Biol       Date:  2012-01-28       Impact factor: 7.727

2.  Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1.

Authors:  Meghan J Seltzer; Bryson D Bennett; Avadhut D Joshi; Ping Gao; Ajit G Thomas; Dana V Ferraris; Takashi Tsukamoto; Camilo J Rojas; Barbara S Slusher; Joshua D Rabinowitz; Chi V Dang; Gregory J Riggins
Journal:  Cancer Res       Date:  2010-11-02       Impact factor: 12.701

3.  The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases.

Authors:  Rasheduzzaman Chowdhury; Kar Kheng Yeoh; Ya-Min Tian; Lars Hillringhaus; Eleanor A Bagg; Nathan R Rose; Ivanhoe K H Leung; Xuan S Li; Esther C Y Woon; Ming Yang; Michael A McDonough; Oliver N King; Ian J Clifton; Robert J Klose; Timothy D W Claridge; Peter J Ratcliffe; Christopher J Schofield; Akane Kawamura
Journal:  EMBO Rep       Date:  2011-04-01       Impact factor: 8.807

4.  IDH mutation impairs histone demethylation and results in a block to cell differentiation.

Authors:  Chao Lu; Patrick S Ward; Gurpreet S Kapoor; Dan Rohle; Sevin Turcan; Omar Abdel-Wahab; Christopher R Edwards; Raya Khanin; Maria E Figueroa; Ari Melnick; Kathryn E Wellen; Donald M O'Rourke; Shelley L Berger; Timothy A Chan; Ross L Levine; Ingo K Mellinghoff; Craig B Thompson
Journal:  Nature       Date:  2012-02-15       Impact factor: 49.962

5.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.

Authors:  Houtan Noushmehr; Daniel J Weisenberger; Kristin Diefes; Heidi S Phillips; Kanan Pujara; Benjamin P Berman; Fei Pan; Christopher E Pelloski; Erik P Sulman; Krishna P Bhat; Roel G W Verhaak; Katherine A Hoadley; D Neil Hayes; Charles M Perou; Heather K Schmidt; Li Ding; Richard K Wilson; David Van Den Berg; Hui Shen; Henrik Bengtsson; Pierre Neuvial; Leslie M Cope; Jonathan Buckley; James G Herman; Stephen B Baylin; Peter W Laird; Kenneth Aldape
Journal:  Cancer Cell       Date:  2010-04-15       Impact factor: 31.743

6.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.

Authors:  Lenny Dang; David W White; Stefan Gross; Bryson D Bennett; Mark A Bittinger; Edward M Driggers; Valeria R Fantin; Hyun Gyung Jang; Shengfang Jin; Marie C Keenan; Kevin M Marks; Robert M Prins; Patrick S Ward; Katharine E Yen; Linda M Liau; Joshua D Rabinowitz; Lewis C Cantley; Craig B Thompson; Matthew G Vander Heiden; Shinsan M Su
Journal:  Nature       Date:  2009-12-10       Impact factor: 49.962

7.  Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.

Authors:  Shimin Zhao; Yan Lin; Wei Xu; Wenqing Jiang; Zhengyu Zha; Pu Wang; Wei Yu; Zhiqiang Li; Lingling Gong; Yingjie Peng; Jianping Ding; Qunying Lei; Kun-Liang Guan; Yue Xiong
Journal:  Science       Date:  2009-04-10       Impact factor: 47.728

8.  Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.

Authors:  Peppi Koivunen; Sungwoo Lee; Christopher G Duncan; Giselle Lopez; Gang Lu; Shakti Ramkissoon; Julie A Losman; Päivi Joensuu; Ulrich Bergmann; Stefan Gross; Jeremy Travins; Samuel Weiss; Ryan Looper; Keith L Ligon; Roel G W Verhaak; Hai Yan; William G Kaelin
Journal:  Nature       Date:  2012-02-15       Impact factor: 49.962

9.  Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.

Authors:  Maria E Figueroa; Omar Abdel-Wahab; Chao Lu; Patrick S Ward; Jay Patel; Alan Shih; Yushan Li; Neha Bhagwat; Aparna Vasanthakumar; Hugo F Fernandez; Martin S Tallman; Zhuoxin Sun; Kristy Wolniak; Justine K Peeters; Wei Liu; Sung E Choe; Valeria R Fantin; Elisabeth Paietta; Bob Löwenberg; Jonathan D Licht; Lucy A Godley; Ruud Delwel; Peter J M Valk; Craig B Thompson; Ross L Levine; Ari Melnick
Journal:  Cancer Cell       Date:  2010-12-09       Impact factor: 38.585

10.  IDH1 and IDH2 mutations in gliomas.

Authors:  Hai Yan; D Williams Parsons; Genglin Jin; Roger McLendon; B Ahmed Rasheed; Weishi Yuan; Ivan Kos; Ines Batinic-Haberle; Siân Jones; Gregory J Riggins; Henry Friedman; Allan Friedman; David Reardon; James Herndon; Kenneth W Kinzler; Victor E Velculescu; Bert Vogelstein; Darell D Bigner
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 176.079
View more
  16 in total

1.  Discovery of a novel calcium-sensitive fluorescent probe for α-ketoglutarate.

Authors:  Lin-Lin Gan; Lin-Hai Chen; Fa-Jun Nan
Journal:  Acta Pharmacol Sin       Date:  2017-07-17       Impact factor: 6.150

Review 2.  Mutant DNA methylation regulators endow hematopoietic stem cells with the preleukemic stem cell property, a requisite of leukemia initiation and relapse.

Authors:  Yuting Tan; Han Liu; Saijuan Chen
Journal:  Front Med       Date:  2015-12       Impact factor: 4.592

Review 3.  Occurrence, Biological Consequences, and Human Health Relevance of Oxidative Stress-Induced DNA Damage.

Authors:  Yang Yu; Yuxiang Cui; Laura J Niedernhofer; Yinsheng Wang
Journal:  Chem Res Toxicol       Date:  2016-11-07       Impact factor: 3.739

Review 4.  High-Grade Sinonasal Carcinoma: Classification Through Molecular Profiling.

Authors:  Julie Guilmette; Peter M Sadow
Journal:  Arch Pathol Lab Med       Date:  2019-02-19       Impact factor: 5.534

5.  AMPK/α-Ketoglutarate Axis Dynamically Mediates DNA Demethylation in the Prdm16 Promoter and Brown Adipogenesis.

Authors:  Qiyuan Yang; Xingwei Liang; Xiaofei Sun; Lupei Zhang; Xing Fu; Carl J Rogers; Anna Berim; Shuming Zhang; Songbo Wang; Bo Wang; Marc Foretz; Benoit Viollet; David R Gang; Buel D Rodgers; Mei-Jun Zhu; Min Du
Journal:  Cell Metab       Date:  2016-09-15       Impact factor: 27.287

6.  Recurrent patterns of DNA methylation in the ZNF154, CASP8, and VHL promoters across a wide spectrum of human solid epithelial tumors and cancer cell lines.

Authors:  Francisco Sánchez-Vega; Valer Gotea; Hanna M Petrykowska; Gennady Margolin; Thomas C Krivak; Julie A DeLoia; Daphne W Bell; Laura Elnitski
Journal:  Epigenetics       Date:  2013-10-22       Impact factor: 4.528

Review 7.  Management of Newly Diagnosed Acute Myeloid Leukemia in the Elderly: Current Strategies and Future Directions.

Authors:  David Sanford; Farhad Ravandi
Journal:  Drugs Aging       Date:  2015-12       Impact factor: 3.923

Review 8.  Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas.

Authors:  Ourania Romanidou; Vassiliki Kotoula; George Fountzilas
Journal:  Cancer Genomics Proteomics       Date:  2018 Sep-Oct       Impact factor: 3.395

9.  Preclinical efficacy against acute myeloid leukaemia of SH1573, a novel mutant IDH2 inhibitor approved for clinical trials in China.

Authors:  Zhiqiang Wang; Zhibo Zhang; Yong Li; Li Sun; Dezhen Peng; Danyu Du; Xian Zhang; Luwei Han; Liwen Zhao; Ligong Lu; Hongzhi Du; Shengtao Yuan; Meixiao Zhan
Journal:  Acta Pharm Sin B       Date:  2021-03-09       Impact factor: 11.413

10.  Solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms (solid papillary carcinomas with reverse polarity) harbour recurrent mutations affecting IDH2 and PIK3CA: a validation cohort.

Authors:  John R Lozada; Thais Basili; Fresia Pareja; Barbara Alemar; Arnaud Da Cruz Paula; Rodrigo Gularte-Merida; Dilip D Giri; Patricia Querzoli; Gabor Cserni; Emad A Rakha; Maria P Foschini; Jorge S Reis-Filho; Edi Brogi; Britta Weigelt; Felipe C Geyer
Journal:  Histopathology       Date:  2018-06-01       Impact factor: 7.778
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.